Lixisenatide, a glucagon‐like peptide‐1 (GLP‐1) receptor agonist, is used in the treatment of type 2 diabetes mellitus (T2DM). It increases insulin (INS) secretion and can decrease INS resistance, improving metabolic disorders in this disease. However, its effects on metabolic disturbances in cancer‐bearing, which also exhibit decreased INS secretion and INS resistance, changes that may contribute to weight loss (cachexia), have not yet been evaluated. The purpose of this study was to investigate the lixisenatide treatment effects on mild cachexia and related metabolic abnormalities in Walker‐256 tumour‐bearing rats. Lixisenatide (50 μg kg⁻¹, SC) was administered once daily, for 6 days, after inoculation of Walker‐256 tumour cells. Acute lixisenatide treatment did not improve hypoinsulinemia, INS secretion and INS resistance of tumour‐bearing rats. It also did not prevent the reduced glucose and increased triacylglycerol and lactate in the blood and nor the loss of retroperitoneal and epididymal fat of these animals. However, acute lixisenatide treatment accentuated the body mass loss of tumour‐bearing rats. Therefore, lixisenatide, unlike T2DM, does not improve hypoinsulinemia and INS resistance associated with cancer, evidencing that it does not have the same beneficial effects in these two diseases. In addition, lixisenatide aggravated weight loss of tumour‐bearing rats, suggesting that its use for treatment of T2DM patients with cancer should be avoided.

中文翻译：

---

利西拉肽治疗对Walker-256荷瘤大鼠轻度恶病质和相关代谢异常的影响

Lixisenatide是一种胰高血糖素样肽-1（GLP-1）受体激动剂，用于治疗2型糖尿病（T2DM）。它可以增加胰岛素（INS）的分泌，并可以降低INS抵抗力，从而改善该疾病的代谢异常。然而，其对癌症中代谢紊乱的影响（还表现出INS分泌减少和INS抗性下降，可能导致体重减轻（恶病质）的变化）尚未得到评估。这项研究的目的是研究利西拉肽对Walker-256荷瘤大鼠轻度恶病质和相关代谢异常的治疗作用。利西拉来（50μgkg ^-1，在接种Walker-256肿瘤细胞后，每天一次，连续6天。急性利西拉来治疗不能改善荷瘤大鼠的低胰岛素血症，INS分泌和INS抗性。它也不能防止血液中葡萄糖的减少，三酰甘油和乳酸的增加，也不能防止这些动物的腹膜后和附睾脂肪的流失。但是，急性利西拉来治疗会加剧荷瘤大鼠的体重减轻。因此，与T2DM不同，利西拉来不能改善与胰岛素相关的低胰岛素血症和INS抵抗性，证明它在这两种疾病中没有相同的有益作用。此外，利西拉来肽可加剧荷瘤大鼠的体重减轻，这表明应避免将其用于治疗T2DM癌症患者。